Skip to main content
OpenTrials
Completed

NCT Number: NCT04779840

Retrospective Study on the Incidence and Management of Anemia in Oncology

The incidence of anemia ranges from 20 to 75% depending on the type of cancer. It is often present at diagnosis and increases with specific treatments. It has an impact on overall survival and quality of life. Its origins are multiple (pure iron deficiency or functional, malnutrition, dyserythropoiesis, insufficiency renal, hemolysis, chemotherapy, radiotherapy, targeted therapies).

Transfusion is the most common treatment offered in the management of anemia. The incidence of anemia and its consequences are often underestimated during cancer management.

Recommendations were published in 2012. An inventory of the incidence of anemia before and after the publication of these recommendations are proposed in order to assess their impact on daily practice.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Anemia Cancer Hematologic Diseases Hemic and Lymphatic Diseases Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Centre Jean Bernard - Clinique Victor Hugo

Le Mans, 72000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years old,
  • Follow-up for cancer justifying hospitalization,
  • Presenting anemia defined by a hemoglobin level <11 g / dL,
  • Patient not having objected to the collection of his data after oral and written information.

Exclusion criteria

  • patients with a hemoglobin level ≥ 11 g / dL,
  • adult patients under guardianship, curatorship or deprived of liberty,
  • pregnancy or breast-feeding in progress at the time of hospitalization.

Treatment and study plan

anemia assessment

Other

evaluation of anemia status

Primary outcomes

  1. Incidence of anemia

    Time frame: 2 years

    number of patient with anemia (<11.0 g/dL) upon admission to hospital on the number of patients hospitalized over the period

Secondary outcomes

  1. Assessment of transfusion prescriptions

    Time frame: 2 years

    number of transfusions performed on the number of patients hospitalized over the period

  2. Assessment of erythropoiesis stimulating agents (EPO) prescriptions

    Time frame: 2 years

    number of prescriptions for erythropoiesis stimulating agents (EPO)

  3. Assessment of iron prescriptions

    Time frame: 2 years

    number of prescriptions of iron (oral and intravenous)

  4. Time between last transfusion and date of death

    Time frame: 2 years

    Delay between the date of the last transfusion and the date of patient's death

  5. overall survival

    Time frame: 2 years

    Delay between the enrollment date and the date of patient's death

Sponsors and collaborators

Lead sponsor

Weprom

Other

Registry information

Acronym: RESPIRE

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Mar 3, 2021
Registry last updated
Mar 3, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.